UNSPSC 51413203: Trimetazidine

This classification denotes a cardiotonic agent with the molecular formula C14H22N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9A0A0R9S8, chemically known as 1-(2,3,4-trimethoxybenzyl)piperazine but generally known as trimetazidine, which bears US NIH Compound Identifier 21109. European Medicines Agency schedules Trimetazidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11306MIG. The term TRIMETAZIDINE is an International Non-Proprietary Name.

UNSPSC 51413203 Trimetazidine, a Commodity code, covers prescription pharmaceutical products sourced by state and local health agencies, emergency medical services, and public health programs. State and local governments buy specific medications under this code to support emergency response, institutional health care, and pharmacy benefit programs. Recent solicitations show demand for individual pharmaceutical line items supplied through established wholesaler networks, with vendors required to meet stringent expiration-date and cold-chain requirements, FDA compliance, and DSCSA certifications. Issuing bodies span city fire rescue departments, state health and human services commissions, and regional cooperative purchasing alliances serving multiple jurisdictions. The City of Tampa, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of municipal, state agency, and multi-state cooperative purchasers active under the code.

Recent activity concentrates in Florida, Texas, and the Upper Midwest. The City of Tampa's sealed-bid solicitation 26P00188 for Advanced Life Support Medications (posted April 24, 2026, due April 8, 2026) sought 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg for Tampa Fire Rescue at an estimated contract value of $40,000.00, with a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with two-year contract terms and incumbent options extending through June 30, 2028. All three solicitations require FDA compliance, Drug Supply Chain Security Act certification, and minimum insurance coverage for vendors.